2024-03-072024-03-072023-11Borrego Écija, S., Pérez Millan, A., Antonell, A., Fort Aznar, L., Kaya Tilki, E., León Halcón, A.,...,Boza Serrano, A. (2023). Galectin-3 is upregulated in frontotemporal dementia patients with subtype specificity. Alzheimer's & Dementia, 2023, 1-12. https://doi.org/10.1002/alz.13536.1552-52601552-5279https://hdl.handle.net/11441/155933INTRODUCTION Neuroinflammation is a major contributor to the progression of frontotemporal dementia (FTD). Galectin-3 (Gal-3), a microglial activation regulator, holds promise as a therapeutic target and potential biomarker. Our study aimed to investigate Gal-3 levels in patients with FTD and assess its diagnostic potential. METHODS We examined Gal-3 levels in brain, serum, and cerebrospinal fluid (CSF) samples of patients with FTD and controls. Multiple linear regressions between Gal-3 levels and other FTD markers were explored. RESULTS Gal-3 levels were increased significantly in patients with FTD, mainly across brain tissue and CSF, compared to controls. Remarkably, Gal-3 levels were higher in cases with tau pathology than TAR-DNA Binding Protein 43 (TDP-43) pathology. Only MAPT mutation carriers displayed increased Gal-3 levels in CSF samples, which correlated with total tau and 14-3-3. DISCUSSION Our findings underscore the potential of Gal-3 as a diagnostic marker for FTD, particularly in MAPT cases, and highlights the relation of Gal-3 with neuronal injury markers.application/pdf12 p.engAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/C9orf72CSFfrontotemporal dementiagalectin-3GRNMAPTmicroglianeuroinflammationinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccess10.1002/alz.13536